富血小板血浆的临床应用

doi:10.3969/j.issn.1671-2587.2021.06.030

临床输血与检验 ›› 2021, Vol. 23 ›› Issue (6): 806-810.DOI: 10.3969/j.issn.1671-2587.2021.06.030

富血小板血浆的临床应用

马婉茹, 聂志扬, 胡俊华

100010 北京医院输血科, 国家老年医学中心, 中国医学科学院老年医学研究院

收稿日期:2021-10-09 出版日期:2021-12-20 发布日期:2021-12-21
通讯作者: 胡俊华,女,副主任技师,硕士,主要从事临床输血及分子检验方面研究,（E-mail）94026185@qq.com。
作者简介:马婉茹（1991-）,女,淮北市濉溪县人,助理研究员,博士,主要从事分子细胞生物学研究,（E-mail）m65717902@126.com。

Received:2021-10-09 Online:2021-12-20 Published:2021-12-21

摘要/Abstract

摘要： 富血小板血浆（platelet-rich plasma,PRP）是血小板浓度高于基础水平3~6倍时,利用全血各成分沉降系数的不同从而离心得到的血小板血浆,其含有多种促进组织修复和再生的细胞因子等生物活性物质,目前已经成为再生医学治疗中的重要部分。本文就PRP制备及其临床应用做一综述,为PRP治疗规范化提供参考。

关键词: 血小板, 生长因子, 炎性因子, 愈合, 再生

中图分类号:

R457

马婉茹, 聂志扬, 胡俊华. 富血小板血浆的临床应用[J]. 临床输血与检验, 2021, 23(6): 806-810.

[1] FANG J,WANG X,JIANG W,et al.Platelet-rich plasma therapy in the treatment of diseases associated with orthopedic injuries[J].Tissue Eng Part B Rev,2020,26(6):571-585.
[2] REURINK G,VERHAAR J A N,TOL J L. More on platelet-rich plasma injections in acute muscle injury[J]. N Engl J Med,2014,371(13):1264-1265.
[3] ZHENG C B,ZHU Q T,LIU X L,et al.Effect of platelet-rich plasma (PRP) concentration on proliferation,neurotrophic function and migration of Schwann cells in vitro[J]. J Tissue Eng Regen Med,2016,10(5):428-436.
[4] ZHANG X J,WANG J W,REN M G,et al.A novel collagen/platelet-rich plasma (COL/PRP) scaffold:preparation and growth factor release analysis[J]. Cell Tissue Bank,2016,17(2):327-334.
[5] MACHLUS K R,THON J N,ITALIANO J E Jr. Interpreting the developmental dance of the megakaryocyte:a review of the cellular and molecular processes mediating platelet formation[J]. Br J Haematol,2014,165(2):227-236.
[6] HA C W,PARK Y B,JANG J W,et al. Variability of the composition of growth factors and cytokines in platelet-rich plasma from the knee with osteoarthritis[J]. Arthrosc J Arthrosc Relat Surg,2019,35(10):2878-2884.e1.
[7] ELZEY B D,TIAN J,JENSEN R J,et al.Platelet-mediated modulation of adaptive immunity. A communication link between innate and adaptive immune compartments[J]. Immunity,2003,19(1):9-19.
[8] IANNACONE M.Platelet-mediated modulation of adaptive immunity[J]. Semin Immunol,2016,28(6):555-560.
[9] BOSWELL S G,COLE B J,SUNDMAN E A,et al.Platelet-rich plasma:a milieu of bioactive factors[J]. Arthroscopy,2012,28(3):429-439.
[10] ASSIRELLI E,FILARDO G,MARIANI E,et al.Effect of two different preparations of platelet-rich plasma on synoviocytes[J]. Knee Surg Sports Traumatol Arthrosc,2015,23(9):2690-2703.
[11] DRAGOO J L,BRAUN H J,DURHAM J L,et al.Comparison of the acute inflammatory response of two commercial platelet-rich plasma systems in healthy rabbit tendons[J]. Am J Sports Med,2012,40(6):1274-1281.
[12] MCCARREL T M,MINAS T,FORTIER L A. Optimization of leukocyte concentration in platelet-rich plasma for the treatment of tendinopathy[J]. J Bone Joint Surg Am,2012,94(19):e143(1-8).
[13] BOSWELL S G,SCHNABEL L V,MOHAMMED H O,et al.Increasing platelet concentrations in leukocyte-reduced platelet-rich plasma decrease collagen gene synthesis in tendons[J].Am J Sports Med,2014,42(1):42-49.
[14] STUDER R K,DECKER K,MELHEM S,et al.Nitric oxide inhibition of IGF-1 stimulated proteoglycan synthesis:role of cGMP[J].J Orthop Res,2003,21(5):914-921.
[15] WU P I K,DIAZ R,BORG-STEIN J. Platelet-rich plasma[J]. Phys Med Rehabilitation Clin N Am,2016,27(4):825-853.
[16] DOHAN EHRENFEST D M,RASMUSSON L,ALBREKTSSON T. Classification of platelet concentrates:from pure platelet-rich plasma (P-PRP) to leucocyte-and platelet-rich fibrin (L-PRF)[J]. Trends Biotechnol,2009,27(3):158-167.
[17] 中国输血协会临床输血管理学专业委员会. 自体富血小板血浆制备技术专家共识[J]. 中国输血杂志,2021,34(7):677-683.
[18] DELONG J M,RUSSELL R P,MAZZOCCA A D.Platelet-rich plasma:the PAW classification system[J]. Arthroscopy,2012,28(7):998-1009.
[19] MAUTNER K,MALANGA G A,SMITH J,et al.A call for a standard classification system for future biologic research:the rationale for new PRP nomenclature[J]. PM&R,2015,7:S53-S59.
[20] MAGALON J,CHATEAU A L,BERTRAND B,et al.DEPA classification:a proposal for standardising PRP use and a retrospective application of available devices[J]. BMJ Open Sport Exerc Med,2016,2(1):e000060.
[21] SANTOS DUARTE LANA J F,PURITA J,PAULUS C,et al. Contributions for classification of platelet rich plasma-proposal of a new classification:MARSPILL[J]. Regen Med,2017,12(5):565-574.
[22] ROSSI L A,MURRAY I R,CHU C R,et al. Classification systems for platelet-rich plasma[J]. Bone Joint J,2019,101-B(8):891-896.
[23] LINERTOVÁ R,DEL PINO-SEDEÑO T,PÉREZ L G,et al. Cost-effectiveness of platelet-rich plasma for diabetic foot ulcer in Spain[J]. Int J Low Extrem Wounds,2021,20(2):119-127.
[24] DIDANGELOS T,KOLIAKOS G,KOUZI K,et al.Accelerated healing of a diabetic foot ulcer using autologous stromal vascular fraction suspended in platelet-rich plasma[J]. Regen Med,2018,13(3):277-281.
[25] YIN S L,YANG X,BI H S,et al.Combined use of autologous stromal vascular fraction cells and platelet-rich plasma for chronic ulceration of the diabetic lower limb improves wound healing[J]. Int J Low Extrem Wounds,2021,20(2):135-142.
[26] 刘春影,周延民. 血小板浓缩物促进周围神经再生的研究进展[J]. 口腔医学研究,2020,36(6):509-511.
[27] SÁNCHEZ M,ANITUA E,DELGADO D,et al. Platelet-rich plasma,a source of autologous growth factors and biomimetic scaffold for peripheral nerve regeneration[J]. Expert Opin Biol Ther,2017,17(2):197-212.
[28] GIANNESSI E,COLI A,STORNELLI M,et al.An autologously generated platelet-rich plasma suturable membrane may enhance peripheral nerve regeneration after neurorraphy in an acute injury model of sciatic nerve neurotmesis[J]. J Reconstr Microsurg,2014,30(9):617-626.
[29] ZHENG C B,ZHU Q T,LIU X L,et al.Improved peripheral nerve regeneration using acellular nerve allografts loaded with platelet-rich plasma[J]. Tissue Eng Part A,2014,20(23/24):3228-3240.
[30] TAKEUCHI M,KAMEI N,SHINOMIYA R,et al.Human platelet-rich plasma promotes axon growth in brain-spinal cord coculture[J]. Neuroreport,2012,23(12):712-716.
[31] RENN T Y,KAO Y H,WANG C C,et al.Anti-inflammatory effects of platelet biomaterials in a macrophage cellular model[J].Vox Sang,2015,109(2):138-147.
[32] SÁNCHEZ M,ANITUA E,DELGADO D,et al. A new strategy to tackle severe knee osteoarthritis:combination of intra-articular and intraosseous injections of Platelet Rich Plasma[J]. Expert Opin Biol Ther,2016,16(5):627-643.
[33] COUDRIET G M,HE J,TRUCCO M,et al.Hepatocyte growth factor modulates interleukin-6 production in bone marrow derived macrophages:implications for inflammatory mediated diseases[J]. PLoS One,2010,5(11):e15384.
[34] ANITUA E,PELACHO B,PRADO R,et al.Infiltration of plasma rich in growth factors enhances in vivo angiogenesis and improves reperfusion and tissue remodeling after severe hind limb ischemia[J]. J Control Release,2015,202:31-39.
[35] KIM J Y,JEON W J,KIM D H,et al.An inside-out vein graft filled with platelet-rich plasma for repair of a short sciatic nerve defect in rats[J]. Neural Regen Res,2014,9(14):1351-1357.
[36] SHIMOMURA Y,CHRISTIANO A M.Biology and genetics of hair[J]. Annu Rev Genomics Hum Genet,2010,11:109-132.
[37] KHATU S S,MORE Y E,GOKHALE N R,et al.Platelet-rich plasma in androgenic alopecia:myth or an effective tool[J]. J Cutan Aesthet Surg,2014,7(2):107-110.
[38] LI Z J,CHOI H I,CHOI D K,et al.Autologous platelet-rich plasma:a potential therapeutic tool for promoting hair growth[J]. Dermatol Surg,2012,38(7 Pt 1):1040-1046.
[39] SOHN K C,SHI G,JANG S,et al.Pitx2,a beta-catenin-regulated transcription factor,regulates the differentiation of outer root sheath cells cultured in vitro[J]. J Dermatol Sci,2009,54(1):6-11.
[40] GKINI M A,KOUSKOUKIS A E,TRIPSIANIS G,et al.Study of platelet-rich plasma injections in the treatment of androgenetic alopecia through an one-year period[J]. J Cutan Aesthet Surg,2014,7(4):213-219.
[41] TRINK A,SORBELLINI E,BEZZOLA P,et al.A randomized,double-blind,placebo-and active-controlled,half-head study to evaluate the effects of platelet-rich plasma on alopecia areata[J]. Br J Dermatol,2013,169(3):690-694.
[42] GENTILE P,GARCOVICH S,BIELLI A,et al.The effect of platelet-rich plasma in hair regrowth:a randomized placebo-controlled trial[J]. Stem Cells Transl Med,2015,4(11):1317-1323.
[43] 邢杰,贾莉,黄海东,等. 自体富血小板血浆治疗中重度干眼的疗效性及安全性[J]. 中国医师进修杂志,2020,43(6):535-539.
[44] 王新法,徐锦堂. 富血小板血浆促猫角膜内皮细胞增殖的研究[J]. 眼科新进展,2011,31(12):1133-1136.
[45] 中国医疗保健国际交流促进会骨科分会. 富血小板血浆在骨关节外科临床应用专家共识(2018年版)[J]. 中华关节外科杂志(电子版),2018,12(5):596-600.
[46] ORYAN A,ALIDADI S,MOSHIRI A,et al.Bone regenerative medicine:classic options,novel strategies,and future directions[J]. J Orthop Surg Res,2014,9(1):18.
[47] SASSOLI C,VALLONE L,TANI A,et al.Combined use of bone marrow-derived mesenchymal stromal cells (BM-MSCs) and platelet rich plasma (PRP) stimulates proliferation and differentiation of myoblasts in vitro:new therapeutic perspectives for skeletal muscle repair/regeneration[J]. Cell Tissue Res,2018,372(3):549-570.
[48] QI Y Y,NIU L,ZHAO T F,et al.Combining mesenchymal stem cell sheets with platelet-rich plasma gel/calcium phosphate particles:a novel strategy to promote bone regeneration[J]. Stem Cell Res Ther,2015,6:256.
[49] ZHANG J Y,WANG JamesH C. PRP treatment effects on degenerative tendinopathy-an in vitro model study[J]. Muscles Ligaments Tendons J,2014,4(1):10-17.
[50] GUEVARA-ALVAREZ A,SCHMITT A,RUSSELL R P,et al.Growth factor delivery vehicles for tendon injuries:Mesenchymal stem cells and Platelet Rich Plasma[J]. Muscles Ligaments Tendons J,2014,4(3):378-385.
[51] MUTO T,KOKUBU T,MIFUNE Y,et al.Effects of platelet-rich plasma and triamcinolone acetonide on interleukin-1ß-stimulated human rotator cuff-derived cells[J]. Bone Jo Res,2016,5(12):602-609.
[52] 李武,聂顺义,刘景刚,等. 富血小板血浆在临床骨科中的应用进展[J]. 实用手外科杂志,2016,30(4):472-475.

富血小板血浆的临床应用

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

关于本刊

作者中心

在线期刊

访问统计

联系我们

[1]	王倩, 杨李辉, 丁天凌, 夏荣. 自体造血干细胞移植中不同预处理方案与血小板输注的临床分析^*[J]. 临床输血与检验, 2021, 23(6): 686-692.
[2]	邱立娟, 付晓艳, 郭凯, 王孟键, 刘禹, 马曙轩. 60例血小板抗体初筛强阳性患儿的抗体效价分析[J]. 临床输血与检验, 2021, 23(6): 704-707.
[3]	王静, 王成云, 顾萍, 张帆, 潘秋辉. 儿童血小板抗体与自身免疫失调的相关因素分析^*[J]. 临床输血与检验, 2021, 23(6): 708-710.
[4]	敬媛媛, 王洁, 李冬妹, 王丽君, 范成艳, 贾延军. 免疫性血小板输注无效患者HLA和/或HPA抗体产生的影响因素分析[J]. 临床输血与检验, 2021, 23(6): 723-727.
[5]	罗梓瑜, 董伟群. 云南地区育龄人群血小板抗原基因多态性初步研究^*[J]. 临床输血与检验, 2021, 23(6): 737-741.
[6]	章晓燕, 张光满. 术前NLR、MLR、PLR和SⅡ检测在判断胃癌淋巴结转移中的应用价值[J]. 临床输血与检验, 2021, 23(6): 783-787.
[7]	唐雯, 袁君, 严京梅, 吴毅, 齐清, 栾建凤, 刘太香, 吴敏慧, 史丽莉, 冯晨晨, 薛敏. 抗体特异性预测方法克服HLA-Ⅰ类抗体所致血小板输注无效患者1例^*[J]. 临床输血与检验, 2021, 23(6): 797-799.
[8]	陈敏, 杨俊鸿. 血小板细菌污染控制与监测研究进展^*[J]. 临床输血与检验, 2021, 23(6): 811-816.
[9]	马铭梓, 王秋实, 于洋. 中国人群新生儿同种免疫性血小板减少症36例文献回顾性分析^*[J]. 临床输血与检验, 2021, 23(5): 585-592.
[10]	杨菁, 周谋, 林放, 施琳颖, 李艳辉, 李文丹, 单桂秋. 负载PRP壳聚糖-明胶复合敷料止血和促愈合效果的初步评价^*[J]. 临床输血与检验, 2021, 23(5): 612-616.
[11]	林俊填, 麦志周, 杨富燕, 伍伟健, 刘运芝, 余玉婷. 艾地苯醌对血小板生物学特性影响的初步研究^*[J]. 临床输血与检验, 2021, 23(5): 628-631.
[12]	廖红梅, 毛伟, 向宇培, 李军. 间隔14~16天多次单采血小板献血者血液生化指标变化的研究^*[J]. 临床输血与检验, 2021, 23(5): 652-654.
[13]	阳智芬, 邹彬彬, 曹丽群, 谢毓滨. 一例抗HLA抗体引起的新生儿同种免疫性血小板减少性紫癜^*[J]. 临床输血与检验, 2021, 23(5): 668-670.
[14]	苑召虎, 魏亚明. 储存血细胞中非编码RNA研究进展^*[J]. 临床输血与检验, 2021, 23(4): 416-420.
[15]	杨晓亚, 高裕华, 刘素蕊, 李烛. 冰冻保存PRP对IL-1β诱导的软骨细胞炎症反应的影响[J]. 临床输血与检验, 2021, 23(4): 442-445.